【レポートの概要（一部）】
1. Report Overview
1. Executive Summary
1.1 The Companion Diagnostics Market Overview
1.2 Companion Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Companion Diagnostics
2.1 The Foundation of Personalised Medicine
2.2 Personalised Medicine: Changing the Patient Treatment Paradigm
2.3 In Vitro Diagnostic (IVD) Tests
2.3.1 Companion Diagnostics: A Type of IVD
2.3.2 Differences between Companion Diagnostics and Theranostics
2.3.4 Biomarkers to Companion Diagnostics
2.3.5 Genomic Biomarkers
2.3.6 Genomic Oncology Biomarkers
2.4 Regulations in the Companion Diagnostics Market
2.4.1 FDA’s Final Guidance on Companion Diagnostics
2.4.2 LDTs: A Changing Landscape
2.5 Encouraging the Contemporaneous Development of Companion Diagnostics
3. The World Companion Diagnostics Market, 2015-2025
3.1 Scope and Limitations
3.2 The Global Companion Diagnostics Market, 2014
3.3 The Global Companion Diagnostics Market Sales Forecast, 2015-2025
3.4 Companion Diagnostics: Outpacing the Rest of the IVD Market
3.5 Companion Diagnostics: Increasing Market Share of the IVD Market
3.6 The Companion Diagnostics Market by Submarket, 2014
3.7 Theranostics: Will Outpace the Rest of the CDx Market
3.8 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2015-2025
4. Leading National Markets for Companion Diagnostics, 2015-2025
4.1 The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2014
4.2 The Leading National Markets for Companion Diagnostics Sales Forecast, 2015-2025
4.2.1 Changing Market Shares of Leading National Markets, 2015-2025
4.3 The US Companion Diagnostics Market Sales Forecast, 2015-2025
4.3.1 The U.S Will Continue to Dominate the Market
4.3.2 Leading Companion Diagnostics U.S Companies
4.4 The EU5 Companion Diagnostics Sales Market, 2014
4.4.1 The EU5 Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.2 Changing Market Shares of the EU5 Companion Diagnostics Market
4.4.3 The German Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.4 The French Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.5 The Italian Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.6 The Spanish Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.7 The UK Companion Diagnostics Market Sales Forecast, 2015-2025
4.5 The Japanese Companion Diagnostics Market Sales Forecast, 2015-2025
4.5.1 Japan’s Slow Medical Technology Regulatory Process
4.6 The Chinese Companion Diagnostics Market Sales Forecast, 2015-2025
4.6.1 Cancer Rates will Drive Adoption of Companion Diagnostic tests
4.6.2 Ventana: A Major Player Moving into China’s Companion Diagnostics Space
4.7 The Indian Companion Diagnostics Market Sales Forecast, 2015-2025
4.8 The Brazilian Companion Diagnostics Market Sales Forecast, 2015-2025
4.9 The Russian Companion Diagnostics Market Sales Forecast, 2015-2025
4.10 The South Korean Companion Diagnostics Market Sales Forecast, 2015-2025
4.11 The Mexican Companion Diagnostics Market Sales Forecast, 2015-2025
4.12 The Rest of the World Companion Diagnostics Market Sales Forecast, 2015-2025
5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships Market
5.1 Biomarkers: At the Forefront of Companion Diagnostics Development
5.2 U.S FDA Approved Companion Diagnostic Tests, 2015
5.3 Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics
5.4 Expensive Cancer Therapies Encourages the Development of CDx
5.5 Other Disease Indication Opportunities in the Companion Diagnostics Market
5.6 Companion Diagnostic/Pharma Partnerships, 2013-2014
6. Business Models and Stakeholders in the Companion Diagnostics
6.1 Business Models for the Development of Companion Diagnostics
6.1.1 The Partnership Model is the Most Practiced Method
6.1.2 The Stand-alone Model: Licensing an IP
6.1.3 The One Stop Shop Model: An Approach by Large Pharma
6.1.4 Using Contract Diagnostics Organisations (CDO): An Emerging Trend
6.2 Factors Driving Companies to Enter the Companion Diagnostics Market
6.3 Stakeholders influencing the Companion Diagnostics Market
6.3.1 Pharmaceutical Companies and Diagnostic Manufacturers
6.3.2 Regulatory Authorities
6.3.3 Testing Laboratories
6.3.4 Physicians and Patients
6.3.5 Payers
6.4 Companion Diagnostics Competitive Landscape, 2015
7. Leading Companies in the Companion Diagnostics Market
7.1 Roche: Global Diagnostics Leader
7.1.1 Ventana Medical Systems (Roche)
7.1.2 Sales and Recent Performance Analysis, 2014
7.1.3 Roche Diagnostics by Region, 2014
7.1.4 Roche: Internal Growth
7.1.5 Approval of Tarceva and Cobas EGFR Mutation Test
7.1.6 Companion Diagnostic Project Pipeline
7.1.7 Roche’s Portfolio of Marketed Companion Diagnostics, 2015
7.1.8 Ventana Companion Diagnostics: New Robust Prototype Assays
7.1.9 Recent Companion Diagnostic External Collaborations, 2014-2015
7.1.9.1 Ventana/Genmab
7.1.9.2 Ferring/ Roche: CDx Development for Infertility Treatment
7.1.9.3 MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials
7.1.9.4 Merck/Ventana: CDx for an Undisclosed Target
7.1.9.5 AstraZeneca/Roche: CDx to Support Target Drug AZD9291
7.1.9.6 Boehringer Ingelheim/Roche
7.1.9.7 ImmunoGene/ Ventana
7.1.9.8 Foundation Medicine/Roche
7.1.9.9 Acquisitions: Bolstering their Genomic-based Diagnostic Technologies
7.2 Qiagen: Leading CDx Collaborator with Pharmaceutical Companies
7.2.1 Sales and Recent Performance Analysis, 2013-2014
7.2.1.1 Sales and Recent Performance Analysis, Q1-Q3 2014
7.2.2 Companion Diagnostics Collaboration Agreements with Pharma, 2014
7.2.2.1 Collaboration with Eli Lilly
7.2.2.2 Collaboration with AstraZeneca
7.2.2.3 Collaboration with Astellas Pharma
7.2.2.4 Collaboration with Novartis
7.2.2.5 Collaborative Agreements with Technology Companies, 2014
7.2.2.5.1 Collaboration with Protagen
7.2.3 Qiagen: CDx Portfolio and Pipeline
7.3 Abbott Molecular: An Established Competitor
7.3.1 Sales and Recent Performance Analysis, 2013-2014
7.3.1.1 Sales and Recent Performance Analysis, Q1-Q3 2014
7.3.2 Abbott Molecular: Expansive Oncology Biomarker Pipeline
7.3.3 Recent Activity
7.3.3.1 Collaboration with Merck
7.3.3.2 Collaborative Efforts with Idera
7.4 Dako (Agilent)
7.4.1 Life Sciences and Diagnostics Business
7.4.2 Agilent Life Sciences and Diagnostics, Sales and recent Performance Analysis, 2014
7.4.3 Agilent: Next Generation Sequencing Platforms
7.4.4 Recent Companion Diagnostic Collaborations
7.4.4.1 Agilent/ Merck: Several Cancer Collaborations
7.4.4.2 Agilent/Pfizer: An Ongoing Collaboration
7.5 Myriad Genetics
7.5.1 Acquisition of Myriad RBM: Increases the Company’s Market Share of Companion Diagnostics
7.5.2 Companion Diagnostic Service Offerings
7.5.3 Sales and Recent Performance Analysis, 2013-2014
7.5.3.1 BART Test: A High Revenue Generating Product
7.5.3.2 Sales and Recent Performance, Q1-Q3 2014
7.5.4 Myriad Genetics Recent Collaborations
7.5.4.1 Myriad/AstraZeneca: Premarket Approval Application
7.5.4.2 Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market
7.5.4.3 Myriad/ TESARO Companion Collaboration
7.6 BioMérieux
7.6.1 Sales and Recent Performance Analysis, 2013-2014
7.6.2 Sales by Region, 2013
7.6.3 Sales and Recent Performance Analysis, Q1-Q3, 2014
7.6.4 FDA Approval for Metastatic Melanoma Companion Diagnostic Test
7.6.5 Companion Diagnostics: Recent M&A Activity & Collaboration
7.6.5.1 Collaboration Gilead Sciences
7.6.5.2 Collaboration with Ipsen
7.6.5.3 Collaboration with Merck
7.7 Siemens Diagnostics
7.7.1 Siemens Diagnostics: Sales and Recent Performance Analysis, 2013-2014
7.7.2 Siemens Healthcare Research and Development for Diagnostics
7.7.3 Recent Companion Diagnostics Partnerships
7.7.3.1 Agreement with Pfizer
7.7.3.2 Collaboration with Janssen Pharmaceutical
7.7.3.3 Partnership with ViiV Healthcare
7.7.3.4 Partnership with Tocagen
7.7.3.5 Siemens Healthcare: An Uncertain Future
7.8 Thermo Fisher Scientific
7.8.1 Sales and Recent Performance Analysis, 2013-2014
7.8.1.1 Sales Performance by Region, 2013
7.8.1.2 Thermo Fisher Scientific Financial Performance, Q1-3Q 2014
7.8.2 Recent Collaborations and Acquisitions
7.8.2.1 Acquisition of Life Technologies
7.8.2.2 Acquisition of Prionics
7.8.2.3 Thermo Fisher: Developing a ‘Universal’ Companion Diagnostics Using Next Generation Sequencing
7.8.2.4 Thermo Fisher Life Technologies Collaborates with Merck Serono
7.9 Lab 21: Fast Grower in Companion Diagnostics
7.9.1 Partnership with IntegraGen
7.9.2 Partnership with an Undisclosed Major Pharmaceutical Company
7.9.3 Lab 21: A Forerunner in Offering FDA approved Companion Diagnostics
7.9.4 New Lung Cancer Companion Diagnostic Service
8. Quantitative Analysis of the Companion Diagnostics Market, 2015-2025
8.1 SWOT Analysis of the Companion Diagnostics Market
8.2 Strengths
8.2.1 A CDx Strategy Decreases the Length of Approval Process
8.2.2 Premium Prices for Companion Diagnostics
8.2.3 A CDx Development Strategy can Generate more Effective Drugs
8.2.4 Therapeutics Tied with CDx can have Safer Profiles
8.2.5 Reducing the Cost of Healthcare
8.2.6 Increased Regulatory Scrutiny on Marketed Drugs
8.2.7 Target Therapies Will Drive the CDx Market
8.3 Weaknesses
8.3.1 Reimbursement Challenges and Undervalue
8.3.2 Lack of Clear Regulatory Guidelines
8.3.3 Capital Intensity is High
8.4 Opportunities
8.4.1 Fast-growing Emerging Markets
8.4.2 Next Generation Sequencing
8.4.3 Full Oncology Pipeline and Other Drug Categories will Benefit from CDx
8.4.4 Many New CDx/ Pharma Company Partnerships
8.5 Threats
8.5.1 Complex Business Models and Business Partnerships
8.5.2 Medical Device Excise Tax
8.6 Porter’s 5 Analysis of the Companion Diagnostics Market
8.6.1 Rivalry Among Competitors [High]
8.6.2 Power of Suppliers [High]
8.6.3 Power of Buyers [Medium]
8.6.4 Threat of New Entrants [Medium]
8.6.5 Threat of Substitutes [High]
9. Expert Opinions
9.1 Interview with Dr Philip D. Cotter, Principal and Co-Founder of ResearchDx, and Laboratory Director of Pacific Diagnostics Clinical Laboratory, a subsidiary of ResearchDx
9.1.1 Contract Diagnostics: A Growing Industry
9.1.2 Identifying Companion Diagnostic Partners During the Drug Development Phase
9.1.3 Oncology is Still the Largest Category for Companion Diagnostics
9.1.4 Timing the CDx/Drug Development Phase is Key to Success
9.1.5 Companion Diagnostics: A Faster Route to Therapy Approval
9.1.6 Next Generation Sequencing: A Necessary Technology?
9.2 Professor Herbie Newell, Professor of Cancer Therapeutics, Northern Institute for Cancer Research
9.2.1 Companion Diagnostics: Also Known as Predictive Biomarkers
9.2.2 Oncology: A Promising Pipeline of Targeted Therapies
9.2.3 Technological Platforms for Biomarker Discovery
9.2.4 Cancer Targets: Some are More Challenging than Others
9.2.5 Beyond Oncology: Biomarkers could Aid Infectives
9.2.6 The Challenges of Heterogeneous Cancers
9.2.7 Cancer Research UK Drug Discovery Programme
10. Conclusion
10.1 Overview
10.2 Theranostics: A Fast Growing Market
10.3 Leading Companion Diagnostic Companies
10.4 Pharmaceutical/Diagnostic Partnership Model
10.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
10.6 Commercial Drivers of the Companion Diagnostics Market
10.7 Commercial Restraints of the Companion Diagnostics Market
10.8 Concluding Remarks
【レポート販売概要】
■ タイトル：コンパニオン診断（CDx）の世界市場■ 英文：The Companion Diagnostics (CDx) Market Forecast 2015-2025
■ 発行日：2015年2月
■ 調査会社：visiongain
■ 商品コード：VGAIN502206
■ 調査対象地域：グローバル
- 締固め機械の世界市場2017-2021About Compaction EquipmentA compactor is a machine or mechanism used to reduce the thickness of materials such as soil, aggregates, concrete, and so on by filling the air voids present in the material. Technavio’s analysts forecast the global Compaction Equipment market to grow at a CAGR of 4.74% during the period 2017-2021. [Covered in this report] The report covers the present scenario and the g …
- 血友病の世界市場：タイプ別（血友病A、血友病B、血友病C）、治療別（オンデマンド療法、予防投与）、治療別（補充療法、遺伝子治療）、セグメント予測The global hemophilia market is expected to reach USD 16.9 billion by 2026, according to a new report by Grand View Research, Inc. Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver. CDC’s National Center on Birth Defects and Developmental Disabilities (NCBDDD) unde …
- HVAC（空調）装置用バルブの世界市場：ボール弁、グローブ弁、バタフライ弁About the Heating, Ventilation, and Air Conditioning (HVAC) Valves Market Valves are devices that regulate, direct, or control the flow of fluids (gases, liquids) by opening, closing, or partially opening various pathways. The three most commonly used types of valves in HVAC systems are: • Ball Valve • Globe Valve • Butterfly Valve Valves play a significant role in fluid distribution in HVAC syste …
- 2014年戦略提言：スペインの血液及びフローサイトメトリー市場Complete report $6,200. DataPack (test volumes, sales forecasts, supplier shares) $3,900.SummaryThis comprehensive report contains 255 pages, 34 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in Spanish hematology and flow cytometry markets during the next five years. The report explores business and …
- Allantoinの世界市場Allantoin (CAS 97-59-6) Market Research Report 2013 presents comprehensive data on allantoin markets globally and regionally (Europe, Asia, North America etc.) The report includes allantoin description, covers its application areas and related patterns. It overviews allantoin market, names allantoin producers and indicates its suppliers. Besides, the report provides allantoin prices in regional ma …
- スマートロックの世界市場予測・分析2019-2023Global Smart Lock Market: About this market Technavio’s smart lock market analysis considers sales from residential and other end-users. Our study also finds the sales of smart lock in APAC, Europe, North America, South America, and MEA. In 2018, the residential segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as facial recogniti …
- 世界の機能性印刷市場：材料、技術、用途、地域別分析The functional printing technology is advancing from research and development into production and is penetrating many applications like sensors, batteries, RFID, photovoltaic, flexible display, and so on. The production of silicon based components using conventional fabrication methods is found to be costly and faces environmental issues. These issues have pushed the demand for low cost and enviro …
- クラウド型Wi-Fiサービス（Wi-Fi as a Service）の世界市場予測（～2021年）The Wi-Fi as a Service market is expected to grow from USD 1.18 Billion in 2016 to USD 5.94 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of 38.1% during the forecast period. Growing demand for centralized management and remote troubleshooting and increasing need for low capital expenditure and total cost of ownership has led to the increased demand for Wi-Fi as a Service. The Wi-Fi as …
- 冷蔵ショーケース（RDC）の世界市場2016-2020：プラグインRDC、リモートRDCAbout Refrigerated Display CasesThe global commercial refrigeration market offers various types of commercial refrigerators such as refrigerated storage cabinets or display cases, ice-making machinery, and walk-in coolers. RDCs are used in supermarkets to provide a temporary storage for perishable food items prior to the sales. In addition to cold storage, RDCs enhance the sales of food products b …
- 2014年戦略提言：Campylobacter診断検査市場The report presents a detailed analysis of the Campylobacter diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Campylobacter definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals &nbs …
- LED照明の世界市場予測（～2022）：設置種類別、最終用途別、製品種類別（ランプ＆照明器具）、地域別“LED lighting market expected to grow at a high rate between 2016 and 2022” The global LED lighting market is expected to be valued at USD 92.40 billion by 2022 and is expected to witness a shipment of 14.01 billion units by 2022, at a CAGR of 13.66% and 21.23%, respectively, between 2016 and 2022. The increasing consumer demand for energy-efficient lighting systems, reduction in prices of LEDs, a …
- 産業用溶接ロボットの世界市場2015-2019About industrial welding robot Industrial robots are programmable automatically-operated machines (or robot systems) that have replaced human effort in industries. They are programmed to automate and control manufacturing processes. They are used in applications such as welding, painting, assembly, product inspection, testing, and packaging. Industrial robots that are used specifically for welding …
- 専用バックアップ装置（PBBA）の世界市場予測（～2024年）“The purpose-built backup appliance market to exhibit significant growth from 2018 to 2024” The purpose-built backup appliance market is expected to grow from USD 5.2 billion in 2019 to USD 8.6 billion by 2024, at a CAGR of 10.6%. The growth of this market can be attributed to the growth of the IoT market, stringent rules and regulation of about data protection and data security such as GDPR (Gene …
- 整形外科用医療機器の世界市場2016-2020About Orthopedic Devices Orthopedic devices are the instruments and implants used in orthopedic surgeries to replace an injured bone or missing joint and to support a damaged bone. These devices can be made of metal, ceramic, or plastic. Technavio’s analysts forecast the global orthopedic devices market to grow at a CAGR of 4.57% during the period 2016-2020. [Covered in this report] The report cov …
- スペインの心臓律動管理（CRM）装置市場見通しSpain Cardiac Rhythm Management (CRM) Procedures Outlook to 2021 Summary GlobalData’s new report, "Spain Cardiac Rhythm Management (CRM) Procedures Outlook to 2021", provides key procedures data on the Spain Cardiac Rhythm Management (CRM) Procedures. The report provides procedure volumes within market segments - Implantable Loop Recorder (ILR) Procedures, Cardiac Resynchronisation Therapy (CRT) P …
